Last reviewed · How we verify
NCT05183087: ReBlast
Long-Term Effects of Repetitive, Low-Level Blast Exposure on Special Operations Forces Service Members
trial testing 3T Connectome MRI in Traumatic Brain Injury in 30 participants. Completed in 28 February 2023.
28 February 2023
Quick facts
| Lead sponsor | Massachusetts General Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 1 July 2021 |
| Primary completion | 28 February 2023 |
| Estimated completion | 28 February 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- 3T Connectome MRI
- 7 Tesla MRI
- TSPO PET — full drug profile →
- Tau PET
- Cognitive and Behavioral Assessments
- Blood Biomarkers — full drug profile →
Conditions studied
- Traumatic Brain Injury — all drugs for Traumatic Brain Injury →
- Blast Injuries — all drugs for Blast Injuries →
Sponsor
Massachusetts General Hospital
Who can join
Adults 25 to 45, male only, with Traumatic Brain Injury or Blast Injuries. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a pilot study to identify biomarkers that individually, and in combination, demonstrate the greatest sensitivity to repetitive, low-level blast exposure (RLLBE) neurotrauma in Special Operations Forces (SOF) personnel. The proposed cross-sectional, multimodal study will elucidate the potential effects of long-term RLLBE by comparing biomarkers across subjects.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
Novel PET Imaging of Inflammatory Targets and Cells for the Diagnosis and Monitoring of Giant Cell Arteritis and Polymyalgia Rheumatica.
van der Geest KSM, Sandovici M, Nienhuis PH, Slart RHJA, et al · · 2022 · cited 21× · PMID 35733858 · DOI 10.3389/fmed.2022.902155 -
Impact of repeated blast exposure on active-duty United States Special Operations Forces.
Gilmore N, Tseng CJ, Maffei C, Tromly SL, et al · · 2024 · cited 20× · PMID 38648470 · DOI 10.1073/pnas.2313568121 -
Long-Term Effects of Repeated Blast Exposure in United States Special Operations Forces Personnel: A Pilot Study Protocol.
Edlow BL, Bodien YG, Baxter T, Belanger HG, et al · · 2022 · cited 18× · PMID 35620901 · DOI 10.1089/neu.2022.0030 -
Neuroinflammation at the Gray-White Matter Interface in Active-Duty U.S. Special Operations Forces.
Edlow BL, Tseng CJ, Gilmore N, McKinney IR, et al · · 2024 · cited 4× · PMID 39744610 · DOI 10.1089/neur.2024.0116 -
From imaging to intervention: emerging potential of PET biomarkers to shape therapeutic strategies for TBI-induced neurodegeneration.
Giarratana AO. · · 2025 · cited 1× · PMID 40837059 · DOI 10.3389/fneur.2025.1637243 -
Tau biomarkers in Special Operations Forces with repeated blast exposure: a cross-sectional study.
Tseng CJ, Guo J, Gilmore N, Greve DN, et al · · 2026 · PMID 41809436 · DOI 10.1093/braincomms/fcag061
Verify or expand the search:
- PubMed search for NCT05183087
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Traumatic Brain Injury
Currently open trials in the same condition.
- NCT07176936 — Improving Speech in Noise Using Noninvasive Stimulation · NA · recruiting
- NCT07473505 — Integrative Bilateral Cervical Sympathetic Blocks for Trauma-Related Symptoms in Special Operations Veterans: A Prospect · recruiting
- NCT07455136 — A Study to Develop a Blood-based Test for Aiding the Diagnosis/Prognosis of Traumatic Brain Injury in Adults and for Mon · recruiting
- NCT07404761 — Safety and Effectiveness of Spatial StimelMD (SSMD) in Subjects With Upper Limb Neuromotor Impairments · NA · recruiting
- NCT07230002 — Effects of Moderate/Severe Traumatic Brain Injury in the Subacute or Chronic Phase on Locomotor Strategies Involved in N · NA · recruiting
Other Massachusetts General Hospital trials
Trials by the same sponsor.
- NCT03585946 — Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis · withdrawn
- NCT07214831 — A Feasibility and Acceptability Study of a Large Language Model-based Chatbot for Brief Alcohol Intervention Among Emerg · NA · not yet recruiting
- NCT06686901 — A Randomized Controlled Trial of a Smartphone Delivered Treatment for Suicidal Thoughts and Behavior · NA · not yet recruiting
- NCT05854212 — Behavioral Economics to Implement Nutrition Ranking in Food Pantries · NA · not yet recruiting
- NCT07323446 — The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05183087 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Massachusetts General Hospital
- Last refreshed: 4 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05183087.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing